Hospital Universitario De Fuenlabrada — Clinical Trial Site

48 Registered trials

22 Currently recruiting

Organisation

Hospital Universitario De Fuenlabrada

Location

Fuenlabrada, Spain

Identifier

ORG-100043812

Address

Camino Del Molino 2, 28942, Spain

Departments

#3427: Medicina Interna
2745; Dermatología
3451: Servicio Dermatología
Allergology
Aparato Digestivo
Cirugía
Dermatology
Dermatology Department
Digestive
Digestivo
Edificio Oncología 2ª planta
Fandiño
Gastroenterology
General and Digestive Surgery
Hematología
Intensive medicine
Internal Medicine
Medical Oncology
Medicina Interna
n/a
Oncolgy
Oncology
Oncology Department
Oncology Service
Rheumatology
Servicio de Alergia
Servicio de aparato digestivo
Servicio de Oncologia

Clinical trials at this site (48)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and … Pending

2025-521989-95-00 Advanced/Metastatic Non-squamous Non-Small Cell Lung Ca 9
Dose determination study of Phleum pratense allergenic extract for immunotherapy treatment, administered via sublingual route, standardized … Pending

2025-522730-31-00 Allergic rhinitis/rhinoconjunctivitis caused by grass p 4
Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Recruiting

2025-521709-42-00 Allergic rhinoconjunctivitis with or without asthma due 5 2026-06-23
Grass Immunotherapy for Rhinitis and Asthma (GIRA) Recruiting

2025-521736-10-00 Allergic rhinoconjunctivitis with or without controlled 5 2026-06-23
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A phase 3 multi-center trial to evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids in children (ag… Recruiting

2023-503630-44-00 Treatment of moderate-to-severe Atopic dermatitis 10 2024-11-20
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Crohn's disease 4 2023-10-23
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer Recruiting

2025-520471-29-00 Locally advanced adenocarcinoma of the colon and upper 5 2026-05-26
LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis: A Phase 2 Study Recruiting

2025-522338-30-00 Ulcerative Colitis 4 2026-03-31
Patient-Centered Study of T-DXd in Metastatic HER2-Positive Breast Cancer with Real-Life Side Effect Management Recruiting

2025-521805-41-00 Patients with HER2-positive, locally advanced or metast 5 2026-02-18
Inhaled sedation in the critically ill patient Recruiting

2024-518521-14-00 Critical condition 6 2025-10-17
A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease ( ENHANCE-CD ) Recruiting

2023-508234-34-00 Crohn's disease 4 2025-01-27
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting

2024-513009-30-00 Moderate to Severe Crohn’s Disease 4 2024-11-21
Double-blind, randomized, placebo-controlled, pilot clinical trial to evaluate the safety, tolerability and efficacy of two doses of a condi… Recruiting

2023-507700-32-00 Acute respiratory distress syndrome (ARDS) caused by SA 1 2024-10-02
STUDY OF OP-1250 ADMINSTERED AS MONOTHERAPY AND COMPARED TO STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST C… Recruiting

2023-505871-63-00 ER+, HER2- metastatic breast cancer following endocrine 5 2024-04-08
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
Multicentre Phase IV clinical trial to evaluate the efficacy of hyperthermic intraoperative chemotherapy (HIPEC) with Mitomycin-C after comp… Recruiting

2024-512726-28-00 peritoneal metastases of colorectal cancer 6 2022-02-14